Get the Stockscreener App
464.71
1.92%
-9.08
After Hours:
455.69
-9.02
-1.94%
Madrigal Pharmaceuticals Inc stock is traded at $464.71, with a volume of 245.70K.
It is down -1.92% in the last 24 hours and down -5.91% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$473.79
Open:
$474.31
24h Volume:
245.70K
Relative Volume:
0.76
Market Cap:
$10.55B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-18.50
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-2.70%
1M Performance:
-5.91%
6M Performance:
+24.43%
1Y Performance:
+32.13%
1-Day Range:
$458.07
$482.99
1-Week Range:
$458.07
$499.55
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
464.71 | 10.76B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 12.04B | 3.95B | 3.34B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Aug Spikes: Is Madrigal Pharmaceuticals Inc stock a value trapMarket Movement Recap & AI Optimized Trade Strategies - baoquankhu1.vn
How Madrigal Pharmaceuticals Inc. (YDO1) stock stacks up against competitors2025 Retail Activity & Daily Market Momentum Tracking - mfd.ru
Why Madrigal Pharmaceuticals Inc. stock is seen as undervaluedWeekly Investment Report & Scalable Portfolio Growth Methods - mfd.ru
Madrigal Pharmaceuticals is Now Oversold (MDGL) - Nasdaq
What are Madrigal Pharmaceuticals Inc.’s recent SEC filings showingMarket Risk Summary & Daily Stock Trend Reports - mfd.ru
MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz
Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Madrigal expands its MASH pipeline via Ribo deal - The Pharma Letter
Madrigal Pharmaceuticals (MDGL) to Release Earnings on Thursday - MarketBeat
Madrigal Pharmaceuticals Expands Team With Equity Awards to New Hires - MSN
Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia
Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com
What are analysts’ price targets for Madrigal Pharmaceuticals Inc.Price Action & Low Risk Growth Stock Ideas - mfd.ru
Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru
Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights
What is Madrigal Pharmaceuticals Inc. s revenue forecastJuly 2025 Update & Accurate Trade Setup Notifications - mfd.ru
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz
Madrigal builds in MASH with $4.4bn+ Ribo alliance - pharmaphorum
Madrigal Pharmaceuticals (MDGL) Secures $4.46B Licensing Deal wi - GuruFocus
Madrigal licenses six Ribo siRNA programs - bioworld.com
Madrigal inks licensing deal for MASH drugs (MDGL:NASDAQ) - Seeking Alpha
Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com
Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com
Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance
Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus
Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - Bitget
Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire
Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by First National Trust Co - MarketBeat
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ribo Life Science Enters Exclusive Licensing Agreement with Madrigal Pharmaceuticals - Intellectia AI
Madrigal Grants Equity to New Hires as MASH Drug Momentum Builds - MyChesCo
Madrigal Sets Date to Reveal 2025 Results as Investors Watch Closely - MyChesCo
Aug Update: Is Madrigal Pharmaceuticals Inc stock good for income investorsRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Madrigal Equity Grants Signal Hiring Push And Undervalued Share Opportunity - Sahm
Madrigal Pharmaceuticals announces grants of inducement awards under Nasdaq Listing Rule - marketscreener.com
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Commit To Buy Madrigal Pharmaceuticals At $350, Earn 14.6% Annualized Using Options - Nasdaq
Federated Hermes Inc. Takes Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Does Madrigal Pharmaceuticals (MDGL) Offer Value After Recent Share Price Weakness - simplywall.st
Madrigal Pharmaceuticals stock maintains Buy rating at B.Riley on strong Rezdiffra growth - Investing.com Canada
Madrigal Pharmaceuticals to report financial results on February 19 - Traders Union
18,291 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Bought by WCM Investment Management LLC - MarketBeat
How (MDGL) Movements Inform Risk Allocation Models - Stock Traders Daily
Novo Set To Make MASH Move On Madrigal In EU With Kayshild - Citeline News & Insights
Madrigal Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026 - Quiver Quantitative
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 - The Manila Times
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.12%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):